Table 1.
Patient baseline characteristics in the SAMBA trial
| Patient characteristics, n, (%) | n = 24 |
|---|---|
| Age (years), median (IQR) | 77 (71–90) |
| AML | 19 (79%) |
| MDS | 5 (21%) |
| Cytogenetics, n, (%) | |
| Normal karyotype | 12 (50%) |
| Abnormal karyotype | 12 (50%) |
| Complex karyotype (≥3) | 5 (21%) |
| ELN 2017 AML risk classification (n = 19) | |
| Favorable | 2 (10%) |
| Intermediate | 8 (43%) |
| Unfavorable | 9 (47%) |
| Somatic mutations, n, (%) | |
| No mutation | 2 (8%) |
| ≥1 mutation | 22 (92%) |
| ≥2 mutations | 16 (67%) |
| ≥3 mutations | 15 (63%) |
| Epigenetic | |
| ASXL1 | 7 (29%) |
| TET2 | 6 (25%) |
| EZH2 | 4 (17%) |
| DNMT3A | 3 (13%) |
| IDH1 | 3 (13%) |
| BCORL1 | 2 (8%) |
| IDH2 | 2 (8%) |
| BCOR | 2 (8%) |
| Cohesin | |
| STAG2 | 4 (17%) |
| RAD21 | 1 (4%) |
| Splicing | |
| SRSF2 | 4 (17%) |
| SF3B1 | 2 (8%) |
| U2AF1 | 2 (8%) |
| ZRSR2 | 2 (8%) |
| Transcription factors | |
| RUNX1 | 3 (13%) |
| CEPBA | 3 (13%) |
| CUX1 | 1 (4%) |
| GATA2 | 1 (4%) |
| TP53 | |
| TP53 | 7 (29%) |
| Signaling | |
| NRAS | 2 (8%) |
| KRAS | 2 (8%) |
| PTPN11 | 2 (8%) |
| JAK2 | 1 (4%) |
| Others | |
| NPM1 | 2 (8%) |
| PHF6 | 2 (8%) |
| KDM6A | 1 (4%) |
| NOTCH1 | 1 (4%) |
| Blood counts, median, (range) | |
| WBC (/nl) | 2.51 (0.37–12.64) |
| Hemoglobin (g/dl) | 9.25 (8.05–11.7) |
| PLT (/nl) | 28 (4–1018) |
| ANC (/nl) | 0.59 (0.0–5.59) |
| Lymphocytes (/nl) | 0.80 (0.024–4) |
| BM blasts (%) | 27 (7–89) |
| Interval from diagnosis (years) | 1.76 (0.61–7.82) |
| Therapy outcome, median, (range) | |
| Days on treatment | 57 (1–374) |
| Cycles completed | 3 (1–26) |